PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy

被引：0

作者：

McDonald, F. ^{[1
]}

Mornex, F. ^{[2
]}

Garassino, M. C. ^{[3
]}

Filippi, A. R. ^{[4
,5
]}

Christoph, D. ^{[6
]}

Haakensen, V. D. ^{[7
]}

Agbarya, A. ^{[8
]}

Van den Heuvel, M. ^{[9
]}

Vercauter, P. ^{[10
]}

Chouaid, C. ^{[11
]}

Pichon, E. ^{[12
]}

Siva, S. ^{[13
]}

Steinbusch, L. ^{[9
]}

Peretz, I. ^{[14
]}

Solomon, B. ^{[15
]}

Decoster, L. ^{[16
]}

Sawyer, W. ^{[17
]}

Allen, A. ^{[18
]}

Licour, M. ^{[19
]}

Girard, N. ^{[20
,21
]}

机构：

[1] Royal Marsden Hosp NHS Fdn Trust, Lung Unit, London, England

[2] Ctr Hosp Univ Lyon, Dept Radiat Oncol, Lyon, France

[3] Ist Nazl Tumori Milano Fdn IRCCS, Div Med Oncol, Milan, Italy

[4] Fdn IRCCS Policlin San Matteo, Dept Radiat Oncol, Pavia, Italy

[5] Univ Pavia, Pavia, Italy

[6] Evangel Kliniken Essen Mitte, Dept Med Oncol, Evangel Huyssens Stiftung, Essen, Germany

[7] Oslo Univ Hosp, Dept Oncol, Oslo, Norway

[8] Bney Zion Med Ctr, Dept Oncol, Haifa, Israel

[9] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

[10] Onze Lieve Vrouw Ziekenhuis Aalst, Dept Pneumol, Aalst, Belgium

[11] CHI Creteil, Serv Pneumol, Creteil, France

[12] CHRU Tours, Serv Pneumol, Hop Bretonneau, Tours, France

[13] Sir Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Australia

[14] Clalit Hlth Serv, Inst Oncol, Tel Aviv, Israel

[15] Univ Melbourne, Sir Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Australia

[16] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Dept Med Oncol, Brussels, Belgium

[17] AstraZeneca, Cambridge, England

[18] AstraZeneca, Gaithersburg, MD USA

[19] Astrazeneca, Paris, France

[20] Inst Curie, Inst Thorax, Paris, France

[21] Montsouris, Paris, France

来源：

JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

79MO

引用

页码：S738 / S739

页数：2

共 50 条

[41] PACIFIC: Overall Survival with Durvalumab versus Placebo after Chemoradiotherapy in Stage III NSCLC
Raben, D.
Faivre-Finn, C.
Spigel, D.
Daniel, D.
Villegas, A.
Vincente, D.
Hui, R.
Carpeno, J. de Castro
Murakami, S.
Paz-Ares, L.
Ozguroglu, M.
Kurata, T.
Chiappori, A.
Lee, K. H.
de Wit, M.
Poole, L.
Wadsworth, C.
Dennis, P. A.
Antonia, S. J.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 102 (05): : 1607 - 1608
[42] Real-world analysis of treatment patterns and efficacy of durvalumab maintenance after chemoradiotherapy in NSCLC patients
Taugner, J.
Kaesmann, L.
Eze, C.
Ruehle, A.
Tufman, A.
Reinmuth, N.
Duell, T. H-G-F.
Belka, C.
Manapov, F.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S742 - S742
[43] Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
Garassino, M. C.
Mazieres, J.
Reck, M.
Chouaid, C.
Bischoff, H.
Reinmuth, N.
Cove-Smith, L. S.
Mansy, T.
Cortinovis, D. L.
Migliorino, M. R.
Delmonte, A.
Sanchez, J. Garcia
Velarde, L. E. Chara
Caro, R. Bernabe
Paz-Ares, L.
Chander, P.
Perez, I. Diaz
Foroutanpour, K.
Faivre-Finn, C.
ANNALS OF ONCOLOGY, 2023, 34 : S1301 - S1302
[44] 5-Year Survival Data of Durvalumab after Chemoradiotherapy for unresectable Stage III NSCLC - an Update from the PACIFIC Study
de Wit, M.
Spigel, D.
Faivre-Finn, C.
Gray, J.
Vicente, D.
Planchard, D.
Paz-Ares, L.
Vansteenkiste, J.
Garassino, M.
Hui, R.
Quantin, X.
Rimner, A.
Wu, Y. -L.
Ozguroglu, M.
Lee, K. H.
Kato, T.
Macpherson, E.
Newton, M.
Thiyagarajah, P.
Antonia, S.
Reck, M.
STRAHLENTHERAPIE UND ONKOLOGIE, 2021, 197 (SUPPL 1) : S8 - S9
[45] Radiological changes and patterns of progression in unresectable stage III NSCLC treated with concurrent chemoradiotherapy (CCRT) and durvalumab
Patel, Rianne
Abdulwahid, Danya
Bayman, Neil
Coote, Joanna
Cove-Smith, Laura
Fenmore, Jackie
Harris, Margaret
Neal, Hilary
Taylor, Paul
Sheikh, Hamid
Woolf, David
Chan, Clara
Faivre-Finn, Corinee
LUNG CANCER, 2023, 178 : S59 - S59
[46] 5-year survival outcomes with durvalumab after chemoradiotherapy in unresectable Stage III NSCLC - an update from the PACIFIC trial
de Wit, M.
Spigel, D. R.
Faivre-Finn, C.
Gray, J. E.
Vicente, D.
Planchard, D.
Paz-Ares, L.
Vansteenkiste, J. F.
Garassino, M. C.
Hui, R.
Quantin, X.
Rimner, A.
Wu, Y. -L
Oezgueroglu, M.
Lee, K. H.
Kato, T.
Macpherson, E.
Newton, M.
Thiyagarajah, P.
Antonia, S. J.
Reck, M.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 109 - 110
[47] Real-world toxicity of consolidation durvalumab following chemoradiotherapy (CRT) in elderly and comorbid patients (pts) with unresectable stage III NSCLC: A multi-centre, Australian experience
Stevens, S.
Nindra, U.
Shahnam, A.
Bray, V.
Pal, A.
Yip, P. Y.
Adam, T.
Nagrial, A.
Lee, J. H.
Boyer, M.
Kao, S. C-H.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S989 - S989
[48] Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)
Zukin, Mauro
Gondim, Victor
Shimada, Andrea Kazumi
Lima, Ellias Magalhaes e Abreu
Mathias, Clarissa
Barra, Williams Fernandes
William Jr, William Nassib
Padoan, Monica
Bittencourt, Yuri
Yamamura, Rosely
Silva, Carlos Eduardo Baston
Rossato, Leticia de Jesus
Monteiro, Caio de Almeida
Jesus, Rafaela Gomes de
Gossling, Gustavo
Gelatti, Ana Caroline Zimmer
JORNAL BRASILEIRO DE PNEUMOLOGIA, 2024, 50 (06)
[49] Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation
Patel, S.
Zhao, S.
Wei, L.
Li, M.
Bertino, E.
Presley, C.
Welliver, M.
Haglund, K.
Palmer, J.
Arnett, A.
Beyer, S.
Mende, E.
Elder, J.
Hardesty, D.
Shields, P.
Carbone, D.
Otterson, G.
Williams, T.
Owen, D.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S363 - S364
[50] Safety and Efficacy Results of Durvalumab following Sequential Chemoradiotherapy (sCRT) in Unresectable Stage III NSCLC (PACIFIC 6)
Heilmann, M.
Garassino, M. C.
Mazieres, J.
Chouaid, C.
Bischoff, H.
Reinmuth, N.
Cove-Smith, L.
Mansy, T.
Cortinovis, D.
Migliorino, M. R.
Delmonte, A.
Sanchez, J. G.
Velarde, L. E. C.
Bernabe, R.
Paz-Ares, L.
Perez, Diaz, I
Trunova, N.
Foroutanpour, K.
Faivre-Finn, C.
Reck, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 97 - 98

← 1 2 3 4 5 →